It has been shown that engineered MSCs with the IFN-β improve the survival of glioblastoma (GBM) mice, resistant CNS malignancies, via enhancing CD8 T cells’ selective postsurgical infiltration and directly inducing tumor cells’ cell-cycle arrest [149, 150]. The gene discussed is CD8A; the disease is glioblastoma.